Today: 11 June 2026
Browse Category

NYSE:ELV 14 January 2026 - 4 June 2026

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth Stock Climbs as Investors Reprice the Turnaround, Not Just the Latest Headline

UnitedHealth shares climbed 3.1% to $396.45 Tuesday after unveiling a new Optum Rx fee-based pricing model and raising 2026 profit guidance. The company reported Q1 revenue of $111.7 billion and adjusted earnings of $7.23 per share. Management said fundamentals are improving but described the turnaround as ongoing. Investors responded to both the PBM overhaul and stronger earnings outlook.
12 May 2026
····
Humana Stock Jumps 11% as Medicare Advantage Hopes Put HUM Shares Back in Play

Humana Stock Jumps 11% as Medicare Advantage Hopes Put HUM Shares Back in Play

Humana shares surged 11.27% to $274.96 on Friday, following CVS’s raised 2026 profit outlook tied to improved medical-cost control. Humana’s own 2026 forecast remains under pressure from lower Medicare Star Ratings and limited funding. First-quarter revenue rose to $39.65 billion, but adjusted earnings fell to $10.31 per share. The company maintained its full-year adjusted earnings forecast at at least $9 a share.
9 May 2026
····
UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Stock Jumps as Centene Results Put Insurer Turnaround Back in Play

UnitedHealth Group shares rose about 4% Tuesday after Centene raised its profit forecast, fueling optimism that medical-cost pressures may be easing for large insurers. UnitedHealth last week lifted its 2026 profit outlook and reported a first-quarter medical care ratio of 83.9%. Centene’s medical loss ratio came in below analyst estimates. UnitedHealth’s Optum unit continues to face cost and contract challenges.
28 April 2026
·····
UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

UnitedHealth Group shares dropped over 4% Friday to $257.04, deepening losses after a 1.6% fall earlier in the week. Humana, Elevance, and Cigna also declined, while the Health Care Select Sector SPDR ETF slipped 1.5%. Analysts expect UnitedHealth’s first-quarter profit to fall 8.1% from last year, with investors focused on April 21 results for signs of easing medical costs.
27 March 2026
·····
UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth stock falls again after FTC insulin deal puts OptumRx back in focus

UnitedHealth shares fell nearly 3% to $275.92 in after-hours trading Wednesday after the FTC announced a 10-year insulin pricing settlement with Cigna’s Express Scripts, increasing scrutiny on OptumRx and CVS Caremark. Investors are watching for an FTC oral argument Feb. 5 and a House hearing on drug prices Feb. 11. CVS and Cigna shares also declined. UnitedHealth did not comment.
5 February 2026
·····
UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth stock bounces even after Truist, JPMorgan trim targets as Medicare Advantage rates loom

UnitedHealth shares rose 1% to $289.75 Monday, outperforming peers as Humana, Elevance, and Cigna declined. Truist and JPMorgan cut price targets but kept positive ratings. Investors focused on Medicare Advantage payment rates and 2026 cost trends after last week’s sector sell-off. Final 2027 Medicare Advantage rates are expected in April.
2 February 2026
·······
Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

Healthcare stocks hold up as defensive bid lingers; Pfizer, Merck earnings set the tone

The Health Care Select Sector SPDR Fund (XLV) rose 0.6% to $154.74 Friday, while the S&P 500 fell 0.43%. Healthcare and consumer staples were the only S&P sectors in positive territory as investors shifted to defensive stocks. Major managed-care shares lagged after a minimal proposed Medicare Advantage rate hike. Pfizer, Merck, and Eli Lilly report earnings next week.
1 February 2026
·····
UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth stock slips after-hours as PBM fee disclosure rule adds fresh pressure on UNH

UnitedHealth shares fell 0.6% to $292.29 in after-hours trading Thursday after the U.S. Labor Department proposed new disclosure rules for pharmacy benefit managers. The proposal would require PBMs to reveal fee and compensation details. Investors are also closely watching upcoming Medicare Advantage rate decisions. Related health insurer stocks showed mixed movement late Thursday.
30 January 2026
·····
Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health stock rises as ELV steadies after cautious 2026 outlook and Medicare rate jitters

Elevance Health shares rose 1% to $345.44 Thursday, leading gains in managed-care stocks after policy and earnings volatility. The company forecast 2026 adjusted EPS of at least $25.50, below analyst expectations, and warned of revenue declines amid Medicaid and ACA headwinds. Medicare Advantage payments are set for a minimal 0.09% increase in 2027, rattling the sector. ACA enrollment for 2026 dropped to about 23 million as subsidies ended.
29 January 2026
·····
Elevance Health stock rebounds nearly 6% after earnings — here’s what matters before Thursday’s trade

Elevance Health stock rebounds nearly 6% after earnings — here’s what matters before Thursday’s trade

Elevance Health shares rose 5.9% to $341.85 Wednesday after plunging 14% the previous session. The insurer projected 2026 adjusted earnings of at least $25.50 per share, below analyst forecasts, and expects a small revenue decline. Fourth-quarter operating revenue rose 10% to $49.3 billion. Medicare Advantage payment changes and rising medical costs continue to drive volatility in managed-care stocks.
29 January 2026
··
Elevance Health ELV stock price jumps 6% after earnings, but 2026 outlook points to revenue dip

Elevance Health ELV stock price jumps 6% after earnings, but 2026 outlook points to revenue dip

Elevance Health shares jumped 6% to $343.14 Wednesday after the company set a 2026 profit floor despite warning of lower revenue. The move followed a $80 billion sector selloff triggered by new Medicare payment proposals. Elevance projected 2026 adjusted earnings of at least $25.50 per share and year-end enrollment up to 43.875 million. Fourth-quarter operating revenue reached $49.3 billion.
28 January 2026
··
Elevance Health stock gets hit by Medicare rate surprise — what traders watch before earnings

Elevance Health stock gets hit by Medicare rate surprise — what traders watch before earnings

Elevance Health shares fell 14.3% to $322.92 Tuesday after a Medicare Advantage rate proposal from CMS projected a net average payment increase of just 0.09%, far below Wall Street expectations. The move triggered a broader selloff in health insurer stocks. Investors are awaiting Elevance’s earnings report Wednesday for updates on pricing and costs. CMS will finalize policy milestones in late February and early April.
28 January 2026
··
Elevance Health stock sinks 14% as Medicare Advantage rate shock hits insurers ahead of earnings

Elevance Health stock sinks 14% as Medicare Advantage rate shock hits insurers ahead of earnings

Elevance Health shares fell 14.3% to $322.92 in after-hours trading Tuesday after CMS announced a nearly flat 2027 Medicare Advantage payment update. The move triggered a sector-wide selloff, with managed-care stocks losing about $80 billion in market value. Investors now await Elevance’s quarterly results due Wednesday morning for further guidance.
28 January 2026
··
Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

Healthcare stocks brace for a busy week as XLV slips, UnitedHealth earnings and Capitol Hill heat loom

XLV fell 0.51% to $157.48 Friday, trailing the S&P 500, which ended flat. Health insurer CEOs faced House scrutiny over rising premiums and consolidation, with UnitedHealth pledging ACA rebates in 2026. UnitedHealth reports earnings Jan. 27, Regeneron on Jan. 30. Corcept Therapeutics jumped 45% after positive ovarian cancer trial results.
24 January 2026
·····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 17.01.2026

TransDigm Group reported $8.83 billion in revenue and $1.87 billion net income, with shares near $1,450 and a P/E of 43.8x. Elevance Health closed at $374.87, with DCF analysis suggesting a 62.9% undervaluation. BlackRock traded at $1,163.17, about 11.6% above its implied value. Commercial Metals ended at $74.42, with DCF pointing to a 37.3% discount to intrinsic value.
17 January 2026
···
Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

Why UnitedHealth stock fell today: UNH slides as Medicare Advantage spotlight returns

UnitedHealth shares fell 2.3% to $331.02 in after-hours trading Friday following a MedPAC report highlighting $76 billion in projected Medicare Advantage overpayments. The drop came ahead of a long holiday weekend and the company’s earnings release set for Jan. 27. Managed-care stocks broadly declined, with Humana down 3.76% and Elevance Health off 1.85%.
17 January 2026
···
UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth stock drops today — what traders are watching before UNH earnings

UnitedHealth shares fell 1.3% to $334.40 Friday, weighing on the Dow as managed-care stocks slid after Trump’s new healthcare proposal. The plan, which would replace insurance subsidies with direct payments to consumers, left policy details unclear and insurers under pressure. UnitedHealth will report 2025 earnings and its 2026 outlook on Jan. 27. Investors are watching for updates on government-plan costs and future guidance.
16 January 2026
······
1 2

Stock Market Today

  • AEVEX (AVEX) Stock Down 26.4% Recently: Undervalued Opportunity?
    June 10, 2026, 10:01 PM EDT. AEVEX's share price has dropped 26.4% in the past week and is down 24.4% year-to-date, currently trading at $20.35. Despite this, a Discounted Cash Flow (DCF) analysis indicates the stock is undervalued by 38.4%, with an estimated intrinsic value of $33.02 per share. The company is currently not generating positive free cash flow, reporting an $87.8 million loss over the last twelve months, but projections show free cash flow improving to $154.6 million by 2030. This contrast between recent share performance and valuation metrics may signal a potential buying opportunity. Investors are encouraged to monitor how the business trajectory and financial outlook evolve amid recent market pressures.

Latest articles

Tech stocks slide after hours, Oracle’s AI spending draws focus

Tech stocks slide after hours, Oracle’s AI spending draws focus

11 June 2026
Semiconductor stocks plunged 3.6%, dragging the S&P 500 technology sector into correction territory—down 11% from its June 2 record—as investors punished AI-linked companies like Oracle and Super Micro Computer for heavy spending and capital raises, signaling a shift in risk appetite amid rising inflation and escalating U.S.-Iran tensions.
Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

Murphy USA Shares Spike 10% After Casey’s Margin Surge Rattles Gas Station Sector

11 June 2026
Murphy USA soared 10.04% to $612.16 as investors seized on Casey’s General Stores’ stronger-than-expected fuel margins, spotlighting sector-wide pump profitability; with Murphy’s own first-quarter fuel contribution up 40.6% and margins at 35.0 cents per gallon, the stock’s jump reflects bets that high margins will persist, though volatility in fuel prices remains a key risk.
Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

Sky Quarry Jumps in After-Hours; Traders Eye June Refinery Restart

11 June 2026
Sky Quarry soared 22.44% to $1.91 on record volume, then jumped to $2.38 after hours, as investors bet on a June refinery restart after repairs and a feedstock shortage crushed Q1 revenue to $383; with just $66,828 in cash and “substantial doubt” about its ability to continue, the stock’s fate hinges on hitting its June production target.
Go toTop